Cemiplimab: all 151 studies that test it
Page 1 of 2. Open to participants first (73), then studies with results posted, then the rest; newest registration first within each.
- Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and NeckRecruitingNCT07869823Early Phase 1
- RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung CancerNot yet recruitingNCT07808138Phase 2
- Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialNot yet recruitingNCT07746388Phase 2
- Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNot yet recruitingNCT07720167Phase 2
- Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT07715734Phase 2
- Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent GlioblastomasNot yet recruitingNCT07620548Phase 2
- REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaRecruitingNCT07594106Phase 1/2
- A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaNot yet recruitingNCT07567469Phase 1/2
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaNot yet recruitingNCT07527325Phase 2
- PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaNot yet recruitingNCT07511036Phase 2
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 2
- Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1Not yet recruitingNCT07450183Phase 2
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)RecruitingNCT07433673Phase 2
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaNot yet recruitingNCT07422363Phase 1
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingNCT07404332Phase 1
- Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabRecruitingNCT07387198Phase 2
- Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsRecruitingNCT07360743Phase 2
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaRecruitingNCT07281417Phase 2
- Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 TrialNot yet recruitingNCT07274384Phase 2
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingNCT07195734Phase 2
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingNCT07188896Phase 2
- A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After TreatmentRecruitingNCT07179315Phase 2
- Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal CancerRecruitingNCT07147231Phase 1/2
- A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCERNot yet recruitingNCT07101848Phase 2
- A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCERNot yet recruitingNCT07101822Phase 2
- Cemiplimab as Maintenance Treatment for Advanced Adrenocortical CancerRecruitingNCT07085572Phase 2
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)RecruitingNCT07058012Phase 2
- Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT CarcinomaRecruitingNCT07050186Phase 2
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerRecruitingNCT07001618Phase 2
- Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) PatientsRecruitingNCT06981325Phase 2
- A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyRecruitingNCT06931717Phase 3
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingNCT06918132Phase 2
- PALACE: Cemiplimab Trial According to ctDNA LevelsRecruitingNCT06917573Phase 2
- A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCRecruitingNCT06908304Phase 3
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingNCT06902376Phase 1
- Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerRecruitingNCT06900595Phase 2
- Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesRecruitingNCT06887088Phase 2
- Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast CancerRecruitingNCT06860815Phase 2
- A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentEnrolling by invitationNCT06848088Phase 2
- A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCRecruitingNCT06826768Phase 1
- Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT06790602Phase 2
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT06769698Phase 2
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung CancerRecruitingNCT06743581Not applicable
- Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyRecruitingNCT06731270Phase 2
- A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell CarcinomaRecruitingNCT06699602Phase 2
- Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerRecruitingNCT06656598Phase 2
- Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid TumorsRecruitingNCT06651593Phase 2
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06616584Phase 2/3
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingNCT06594991Phase 2
- Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell CarcinomaRecruitingNCT06585410Phase 3
- Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaRecruitingNCT06528769Phase 2
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 1
- A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRecruitingNCT06469281Phase 1
- Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk FeaturesRecruitingNCT06449313Phase 2
- Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell CarcinomaRecruitingNCT06448026Phase 2
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT06418724Phase 2
- A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyRecruitingNCT06413680Phase 1/2
- A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C MutationsRecruitingNCT06412198Phase 1/2
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingNCT06246916Phase 3
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruitingNCT06121180Phase 2
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCRecruitingNCT06088771Phase 1/2
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 1
- PD-1 +/- IL-4 Inhibition in ER+ Breast CancerNot yet recruitingNCT05967884Phase 2
- Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
- Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckEnrolling by invitationNCT05376553Phase 1
- Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N CaRecruitingNCT04988074Phase 2
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT04975152Phase 1
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingNCT04590326Phase 1/2
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingNCT04253964Phase 2
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsRecruitingNCT03972657Phase 1/2
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingNCT03564340Phase 1/2
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)CompletedNCT05259696Phase 1/2Results posted
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results posted
- A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)TerminatedNCT04913220Phase 1/2Results posted
- Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line ChemotherapyCompletedNCT04646005Phase 2Results posted
- A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentCompletedNCT04526899Phase 2Results posted
- PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)TerminatedNCT04382898Phase 1/2Results posted
- Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast CancerActive, not recruitingNCT04243616Phase 2Results posted
- Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCCTerminatedNCT04242173Phase 2Results posted
- Plerixafor and Cemiplimab in Metastatic Pancreatic CancerCompletedNCT04177810Phase 2Results posted
- Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell CarcinomaCompletedNCT04154943Phase 2Results posted
- Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaTerminatedNCT04006119Phase 2Results posted
- Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cARTTerminatedNCT03787095Phase 1/2Results posted
- A Study of Isatuximab-based Therapy in Participants With LymphomaTerminatedNCT03769181Phase 1/2Results posted
- REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent GliomaTerminatedNCT03690869Phase 1/2Results posted
- REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung CancerTerminatedNCT03515629Phase 3Results posted
- A Study of REGN2810 and Ipilimumab in Patients With Lung CancerTerminatedNCT03430063Phase 2Results posted
- Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerCompletedNCT03409614Phase 3Results posted
- Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced MalignanciesTerminatedNCT03367819Phase 1/2Results posted
- A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaCompletedNCT03294083Phase 1/2Results posted
- Study of Cemiplimab in Adults With Cervical CancerCompletedNCT03257267Phase 3Results posted
- Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsCompletedNCT03194867Phase 1/2Results posted
- PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor TherapyCompletedNCT03132636Phase 2Results posted
- Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03088540Phase 3Results posted
- Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell CarcinomaCompletedNCT02760498Phase 2Results posted
- A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder CancerWithdrawnNCT07414992Phase 2
- Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung CancerWithdrawnNCT06943664Phase 2
- Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCCActive, not recruitingNCT06855212Phase 2